EFL070
For our 70th episode, we review a paper that tries to improve our understanding of remission in Graves’ disease. Long-term thionamide treatment has long been the preferred approach internationally in Graves’ disease, and only more recently here in the U.S. So, the more we know about dosing and how that might encourage or predict remission, the better. This report is an observational study, as is often the case with the papers we look at, so we will discuss how these authors approach this question and share our thoughts along the way. Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, talks with regular contributor Andy Crawford, MD, from Dartmouth-Hitchcock Medical Center, and guest expert Giuseppe Barbesino, MD, from Harvard Medical School in Boston. They discuss "Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves' Disease" by Miyamura et al., published in the August 2025 issue of JCEM.
Meet the Speakers
Regular Contributor
Andrew Crawford, MD, Dartmouth-Hitchcock Medical Center
He attended Brown University where he obtained an ScB in Biology and his MD. He completed Internal Medicine residency and Endocrinology, Diabetes and Metabolism fellowship training at the Hospital of the University of Pennsylvania. He is currently an Assistant Professor of Medicine and Medical Education and Program Director of the Fellowship Program in the Endocrinology Section at Dartmouth Hitchcock Medical Center in Lebanon, NH. His clinical focus is on the evaluation and management of thyroid disease, especially thyroid nodules, thyroid cancer and hyperthyroidism.
Guest Expert
Giuseppe Barbesino, MD, Harvard Medical School, Boston.
Giuseppe Barbesino is an Assistant Professor of Medicine at the Harvard Medical School in Boston. He is a full time Assistant in the Thyroid Unit at the Massachusetts General Hospital in Boston. He graduated from medical School at the Catholic University of Sacred Heart in Rome. He has completed his postgraduate training at the University of Pisa, Italy, at the Mount Sinai School of Medicine in New York and at the University of Massachusetts Medical School in Worcester. Dr. Barbesino's research interests have been mostly directed to the understanding of the genetics of thyroid autoimmune disease, clinical aspects of thyroid cancer. As a full-time faculty member of the Thyroid Unit he is now mostly involved in the care of patients with hyperthyroidism, thyroid nodules and thyroid cancer and in the teaching to medical students, residents and fellows within the Harvard Medical School system.
Everything said on the podcast represents individuals’ opinions only and not those of the participants’ institutions or of the Endocrine Society.
Resources
Meet the Host
Chase Hendrickson, MD, MPH, MMHC, practices general endocrinology at the Vanderbilt University Medical Center, where he is an associate program director for the endocrinology fellowship program. His interests include endocrine education, teaching inferential methods, and quality improvement.
Subscribe
Stay up to date by copying the following into your podcast player:
https://www.endocrine.org/-/media/endosociety/files/podcasts/efl/efl.xml
Or you can find us on the following streaming services:
